Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Betalutin (177Lu-satetraxetan-lilotomab)
i
Other names:
177Lu-DOTA-tetulomab, 177Lu-DOTA-HH1, Lymrit 37-05, HH1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Twitter
Trials
Company:
Nordic Nanovector
Drug class:
Ionizing radiation emitter, CD37 inhibitor
Related drugs:
‹
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
177Lu-FAP-2286 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
lutetium Lu 177 dotatate (1)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
177Lu-FAP-2286 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
lutetium Lu 177 dotatate (1)
›
Associations
(4)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ERBB3 expression
Renal Cell Carcinoma
ERBB3 expression
Renal Cell Carcinoma
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1wk
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1 week - (New D)
ERBB3 expression
Prostate Cancer
ERBB3 expression
Prostate Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1wk
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1 week - (New D)
ERBB3 expression
Colorectal Cancer
ERBB3 expression
Colorectal Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1wk
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1 week - (New D)
ERBB3 expression
Ovarian Cancer
ERBB3 expression
Ovarian Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1wk
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
AACR 2023 - 1 week
177Lu-satetraxetan-lilotomab
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login